Introduction
A new oral medication is generating optimism among oncology researchers after early clinical data showed it could shrink or eliminate tumours in people with advanced pancreatic cancer. The drug, taken daily alongside standard chemotherapy, produced measurable responses in the majority of trial participants. While specialists emphasize that the findings are preliminary and not a cure, they describe the outcome as one of the most encouraging developments in years for a disease with historically poor outcomes.
What Happened
Researchers tested daraxonrasib, a KRAS inhibitor, in combination with chemotherapy among 61 patients recently diagnosed with metastatic pancreatic cancer. According to the trial results, tumours ceased growing in roughly 90% of participants. Just over 60% experienced tumour shrinkage or complete disappearance on imaging. In about 8% of cases—one in 12—scans could no longer detect any tumour. Patients were monitored for approximately 18 months on average, and some remained without disease recurrence during that window. The findings were shared at the EORTC conference, a European oncology meeting.
Why This Matters
Pancreatic cancer remains one of the most difficult malignancies to treat. In the United Kingdom, it accounts for the lowest survival rate among common cancers, with around 11,500 new diagnoses and roughly 10,200 deaths annually. Many patients with advanced disease live only months after diagnosis. Because existing chemotherapy often provides only temporary shrinkage before the cancer returns, any therapy that extends disease control could represent a meaningful shift. Daraxonrasib works by targeting RAS mutations, which drive tumour growth in most pancreatic cancers. The drug has already received approval in the United States, and because similar mutations appear in other cancers such as lung and ovarian cancer, the approach may eventually benefit a broader patient group.
Key Takeaways
- The trial involved 61 people with advanced pancreatic cancer that had spread.
- Tumour growth stopped in approximately 90% of participants.
- Just over 60% saw their tumours shrink or vanish.
- Around 8% had tumours that became undetectable on scans.
- Researchers caution that longer follow-up is required to determine whether the cancer can stay in remission.
- The treatment is not yet considered a cure.
Conclusion
The early results offer a reason for cautious hope, but experts agree that larger, longer trials are essential before any firm conclusions can be drawn about survival benefits or remission. Oncologists stress that scans showing no visible cancer do not guarantee the disease is gone for good. Still, for a condition where progress has been slow and survival statistics remain grim, the data suggest a potential new avenue for extending patients' lives and buying them more time.

Discussion
Join the conversation
Thoughtful reactions, questions, and follow-up ideas help shape the next story.